PP01.74 Clinical Validation of a Promising New Amplicon-Based Liquid Biopsy Platform for Detection of Guideline Recommended Biomarkers in Metastatic NSCLC

Tissue profiling is the gold standard for guideline-recommended biomarker testing for treatment selection in non-squamous non-small cell lung cancer (NSCLC). However, such testing is not accomplishable in 15-40% of patients due to insufficient tissue. For such patients, liquid biopsy potentially offers a swift, comprehensive and non-invasive option for the testing of guideline-recommended biomarkers. For NSCLC, the 9 guideline-recommended biomarkers (G9) include specific somatic alterations in EGFR, ALK, ROS1, RET, BRAF V600E, MET, KRAS G12C, ERBB2/HER2 and NTRK1/2/3. LiquidHALLMARK is an amplicon-based next generation sequencing (NGS) liquid biopsy test, intended to detect alterations in 80 genes and 10 fusions in plasma.